Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
sidered to improve postoperative survival [1][2][3]. A recent trend in the treatment of early gastric cancer, however, involves less invasive or limited surgery to improve the patient's quality of life [4][5][6]. Recent investigations have reported that micrometastases to lymph nodes that were overlooked by ordinary hematoxylin and eosin (H&E) staining could be detected by cytokeratin (CK) immunostaining, and these so-called micrometastases were found to have prognostic significance [7][8][9][10]. Mucosal gastric cancer (m-cancer) has been the prime candidate for less invasive surgery or endoscopic mucosal resection (EMR) [11,12]. However, the frequency or outcome of occult involvement in lymph nodes from m-cancer remains unclear. In this study, in order to assess the critical indications for EMR or less invasive surgery for m-cancer, we investigated the incidence of micrometastasis in lymph nodes in mcancer, using CK immunostaining. Patients and methodsA total of 84 patients (46 men and 38 women) with mcancer, who underwent curative gastrectomy combined with lymphadenectomy at our hospital between 1986 and 1991, were investigated. The patients ranged in age from 37 to 82 years, with a mean age of 63 years. Total gastrectomy was performed in 6 patients (7%), and distal and proximal subtotal gastrectomies in 71 patients (85%) and 7 patients (8%), respectively. Fifty-eight patients underwent standard D2 lymphadenectomy. D2 plus part of group 3 lymph node dissections (lymph nodes in the hepatoduodenal ligament, around the common hepatic artery, behind the head of the pancreas, or at the root of the mesentery) were performed in 26 patients. All of the patients were followed-up for more than 5 years after surgery.Clinicopathologic data were evaluated according to the General rules for gastric cancer study in surgery and Abstract Background. Endoscopic mucosal resection is frequently used in the treatment of mucosal gastric cancer. Micrometastasis in the lymph nodes of mucosal gastric cancer remains unclear. Methods. We examined 2526 lymph nodes from 84 patients with mucosal gastric cancer. Two consecutive sections were prepared, for simultaneous staining with hematoxylin and eosin and immunostaining with CAM 5.2 monoclonal antibody against cytokeratin (CK), respectively. A clinicopathological comparison was made between patients with and without lymph node involvement. Results. Lymph node involvement was detected in 45 of 2526 (1.8%) lymph nodes. The incidence of nodal involvement was significantly increased, from 1.2% (1/84 patients) with hematoxylin and eosin staining, to 19% (16/84 patients) with CK immunostaining. Although no significant difference was found, micrometastasis to lymph nodes was more frequently detected in tumors larger than 1.0 cm (15/72 patients, 21%) than in those less than or equal to 1.0 cm (1/12 patients; 8%, P ؍ 0.307). However, discrete CK-positive cancer cells or clusters of CK-positive cancer cells were detected only in tumors larger than 2 cm. Conclusion. Because mucosal gastric cancer...
sidered to improve postoperative survival [1][2][3]. A recent trend in the treatment of early gastric cancer, however, involves less invasive or limited surgery to improve the patient's quality of life [4][5][6]. Recent investigations have reported that micrometastases to lymph nodes that were overlooked by ordinary hematoxylin and eosin (H&E) staining could be detected by cytokeratin (CK) immunostaining, and these so-called micrometastases were found to have prognostic significance [7][8][9][10]. Mucosal gastric cancer (m-cancer) has been the prime candidate for less invasive surgery or endoscopic mucosal resection (EMR) [11,12]. However, the frequency or outcome of occult involvement in lymph nodes from m-cancer remains unclear. In this study, in order to assess the critical indications for EMR or less invasive surgery for m-cancer, we investigated the incidence of micrometastasis in lymph nodes in mcancer, using CK immunostaining. Patients and methodsA total of 84 patients (46 men and 38 women) with mcancer, who underwent curative gastrectomy combined with lymphadenectomy at our hospital between 1986 and 1991, were investigated. The patients ranged in age from 37 to 82 years, with a mean age of 63 years. Total gastrectomy was performed in 6 patients (7%), and distal and proximal subtotal gastrectomies in 71 patients (85%) and 7 patients (8%), respectively. Fifty-eight patients underwent standard D2 lymphadenectomy. D2 plus part of group 3 lymph node dissections (lymph nodes in the hepatoduodenal ligament, around the common hepatic artery, behind the head of the pancreas, or at the root of the mesentery) were performed in 26 patients. All of the patients were followed-up for more than 5 years after surgery.Clinicopathologic data were evaluated according to the General rules for gastric cancer study in surgery and Abstract Background. Endoscopic mucosal resection is frequently used in the treatment of mucosal gastric cancer. Micrometastasis in the lymph nodes of mucosal gastric cancer remains unclear. Methods. We examined 2526 lymph nodes from 84 patients with mucosal gastric cancer. Two consecutive sections were prepared, for simultaneous staining with hematoxylin and eosin and immunostaining with CAM 5.2 monoclonal antibody against cytokeratin (CK), respectively. A clinicopathological comparison was made between patients with and without lymph node involvement. Results. Lymph node involvement was detected in 45 of 2526 (1.8%) lymph nodes. The incidence of nodal involvement was significantly increased, from 1.2% (1/84 patients) with hematoxylin and eosin staining, to 19% (16/84 patients) with CK immunostaining. Although no significant difference was found, micrometastasis to lymph nodes was more frequently detected in tumors larger than 1.0 cm (15/72 patients, 21%) than in those less than or equal to 1.0 cm (1/12 patients; 8%, P ؍ 0.307). However, discrete CK-positive cancer cells or clusters of CK-positive cancer cells were detected only in tumors larger than 2 cm. Conclusion. Because mucosal gastric cancer...
BackgroundThere have been no reports discussing which imaging procedures are truly necessary before treatment of endoscopically-diagnosed early gastric cancer (eEGC). The aim of this pilot study was to show which imaging examinations are essential to select indicated treatment or appropriate strategy in patients with eEGC.MethodsIn 140 consecutive patients (95 men, 45 women; age, 66.4 +/- 11.3 years [mean +/- standard deviation], range, 33-90) with eEGC which were diagnosed during two years, the pre-treatment results of ultrasonography (US) and contrast-enhanced computed tomography (CT) of the abdomen, barium enema (BE) and chest radiography (CR) were retrospectively reviewed. Useful findings that might affect indication or strategy were evaluated.ResultsUS demonstrated useful findings in 13 of 140 patients (9.3%): biliary tract stones (n = 11) and other malignant tumors (n = 2). Only one useful finding was demonstrated on CT (pancreatic intraductal papillary mucinous tumor) but not on US (0.7%; 95% confidential interval [CI], 2.1%). BE demonstrated colorectal carcinomas in six patients and polyps in 10 patients, altering treatment strategy (11.4%; 95%CI, 6.1-16.7%). Of these, only two colorectal carcinomas were detected on CT. CR showed three relevant findings (2.1%): pulmonary carcinoma (n = 1) and cardiomegaly (n = 2). Seventy-nine patients (56%) were treated surgically and 56 patients were treated by endoscopic intervention. The remaining five patients received no treatment due to various reasons.ConclusionsUS, BE and CR may be essential as pre-treatment imaging examinations because they occasionally detect findings which affect treatment indication and strategy, although abdominal contrast-enhanced CT rarely provide additional information.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.